Αννίται	RURDEN	ESTIMATES
---------	--------	------------------

Instrument	Number of respondents	Number of responses per respondent	Average bur- den hours per response	Total burden hours
ACF–301Estimated Total Annual Burden Hours: 189.	54	1	3.5	189

In compliance with the requirements of Section 3506(c)(2)(A) of the Paperwork Reduction Act of 1995, the Administration for Children and Families is soliciting public comment on the specific aspects of the information collection described above. Copies of the proposed collection of information can be obtained and comments may be forwarded by writing to the Administration for Children and Families, Office of Information Services, Division of Information Resource Management Services, 370 L'Enfant Promenade, SW., Washington, DC 20447, Attn: ACF Reports Clearance Officer. All requests should be identified by title.

In addition, requests for copies may be made and comments forwarded to the Reports Clearance Officer over the Internet by sending message to rsargis@acf.dhhs.gov. Internet messages must be submitted as an ASCII file without special characters or encryption.

The Department specifically requests comments on: (a) Whether the proposed collection of information is necessary for the proper performance of the functions of the agency, including whether the information shall have practical utility; (b) the accuracy of the agency's estimate of the burden of the proposed collection of information; (c) ways to enhance the quality, utility, and clarity of the information to be collected; and (d) ways to minimize the burden of the collection of information on respondents, including through the use of automated collection techniques or other forms of information technology. Consideration will be given to comments and suggestions submitted within 60 days of this publication.

Dated: May 16, 1996.

Bob Sargis,

Reports Clearance Officer.

[FR Doc. 96-12809 Filed 5-21-96; 8:45 am]

BILLING CODE 4184-01-M

Federal Allotments to States for Social Services Expenditures, Pursuant to Title XX, Block Grants to States for Social Services; Revised Promulgation for Fiscal Year 1996

AGENCY: Administration for Children and Families, Department of Health and Human Services.

ACTION: Notification of revised allocation of title XX—social services

block grant allotments for Fiscal Year 1996.

SUMMARY: This issuance sets forth the individual allotments to States for Fiscal Year 1996, pursuant to title XX of the Social Security Act, as amended (Act). This revision is required by Public Law 104–134, the Omnibus Consolidated Rescissions and Appropriations Act of 1996, which decreased the amount available for title XX allotments to \$2,381 billion.

FOR FURTHER INFORMATION CONTACT: Frank A. Burns, (202) 401–5536.

SUPPLEMENTARY INFORMATION: For Fiscal Year 1996, the allotments are based upon the Bureau of Census population statistics contained in its reports "Updated National/State Population Estimates" (CB94–43 Table 1) released March 1994, and "1990 Census of Population and Housing" (CPH–6–AS and CPH–6–CNMI) published April 1992, which was the most recent data available from the Department of Commerce at the time of the Department's initial promulgation.

EFFECTIVE DATE: The allotments are effective October 1, 1995.

FISCAL YEAR 1996 FEDERAL ALLOTMENTS TO STATES FOR SOCIAL SERVICES—TITLE XX BLOCK GRANTS

	Initial FY 96 allotment	Revised FY 96 allotment
TOTAL	\$2,800,000,000	\$2,381,000,000
ALABAMA	45,202,466	38,438,240
ALASKA	6,477,545	5,508,227
AMERICAN SAMOA	104,188	88,597
ARIZONA	42,492,693	36,133,964
ARKANSAS	26,169,280	22,253,234
CALIFORNIA	336,951,078	286,528,750
COLORADO	38,498,207	32,737,226
CONNECTICUT	35,378,190	30,084,096
DELAWARE	7,567,931	6,435,445
DIST. OF COL.	6,250,831	5,315,439
FLORIDA	147,677,222	125,578,382
GEORGIA	74,675,294	63,500,670
GUAM	482,759	410,515
HAWAII	12,663,600	10,768,583
IDAHO	11,875,499	10,098,416
ILLINOIS	126,279,733	107,382,874
INDIANA	61,677,021	52,447,495
IOWA	30,379,684	25,833,582
KANSAS	27,324,443	23,235,536
KENTUCKY	40,905,695	34,784,451
LOUISIANA	46,368,424	39,429,720
MAINE	13,376,130	11,374,488
MARYLAND	53,601,682	45,580,573
MASSACHUSETTS	64,904,998	55,192,429

FISCAL YEAR 1996 FEDERAL ALLOTMENTS TO STATES FOR SOCIAL SERVICES—TITLE XX BLOCK GRANTS—Continued

	Initial FY 96 allotment	Revised FY 96 allotment
MICHIGAN	102,323,614	87,011,617
MINNESOTA	48,765,115	41,467,764
MISSISSIPPI	28,533,584	24,263,738
MISSOURI	56,505,781	48,050,095
MONTANA	9,068,563	7,711,516
NEBRASKA	17,349,024	14,752,866
NEVADA	14,995,516	12,751,544
NEW HAMPSHIRE	12,156,192	10,337,105
NEW JERSEY	85,060,957	72,332,192
NEW MEXICO	17,446,187	14,835,490
NEW YORK	196,453,134	167,055,326
NORTH CAROLINA	74,977,580	63.757.721
NORTH DAKOTA	6,866,197	5,838,721
NO. MARIANA ISLANDS	96,552	82,103
OHIO	119,737,413	101,819,564
OKLAHOMA	34,881,578	29,661,800
OREGON	32,733,192	27,834,905
PENNSYLVANIA	129,982,730	110,531,742
PUERTO RICO	14,482,759	12,315,515
RHODE ISLAND	10,806,704	9,189,557
SOUTH CAROLINA	39,329,492	33,444,114
SOUTH DAKOTA	7,729,870	6,573,150
TENNESSEE	55,048,334	46,810,744
TEXAS	194,661,013	165,531,384
UTAH	20,080,388	17,075,502
VERMONT	6,229,239	5,297,077
VIRGIN ISLANDS	482,759	410,515
VIRGINIA	70,076,237	59,589,828
WASHINGTON	56,732,495	48,242,884
WEST VIRGINIA	19,648,552	16,708,287
WISCONSIN	54,389,783	46,250,742
WYOMING	5,084,873	4,323,960

DATED: May 10, 1996.

Donald Sykes,

Director Office of Community Services. [FR Doc. 96–12860 Filed 5–21–96; 8:45 am]

BILLING CODE 4184-01-P

Food and Drug Administration

Advisory Committees; Notice of Meetings

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: This notice announces forthcoming meetings of public advisory committees of the Food and Drug Administration (FDA). This notice also summarizes the procedures for the meetings and methods by which interested persons may participate in open public hearings before FDA's advisory committees.

FDA has established an Advisory Committee Information Hotline (the hotline) using a voice-mail telephone system. The hotline provides the public with access to the most current information on FDA advisory committee meetings. The advisory committee hotline, which will disseminate current information and information updates,

can be accessed by dialing 1–800–741–8138 or 301–443–0572. Each advisory committee is assigned a 5-digit number. This 5-digit number will appear in each individual notice of meeting. The hotline will enable the public to obtain information about a particular advisory committee by using the committee's 5-digit number. Information in the hotline is preliminary and may change before a meeting is actually held. The hotline will be updated when such changes are made.

MEETINGS: The following advisory committee meetings are announced:

Peripheral and Central Nervous System Drugs Advisory Committee

Date, time, and place. June 6, 1996, 8:30 a.m., Holiday Inn—Bethesda, Versailles Ballrooms III and IV, 8120 Wisconsin Ave., Bethesda, MD.

Type of meeting and contact person. Open public hearing, 8:30 a.m. to 9 a.m., unless public participation does not last that long; open committee discussion, 9 a.m. to 3 p.m.; open public hearing, 3 p.m. to 3:30 p.m., unless public participation does not last that long; William Freas or Sheila D. Langford, Center for Biologics Evaluation and Research (HFM–21), Food and Drug Administration, 1401 Rockville Pike,

Bethesda, MD 20852, 301–827–0314, or FDA Advisory Committee Information Hotline, 1–800–741–8138 (301–443–0572 in the Washington, DC area), Peripheral and Central Nervous System Drugs Advisory Committee, code 12543. Please call the hotline for information concerning any possible changes.

General function of the committee. The committee reviews and evaluates data on the safety and effectiveness of marketed and investigational human drugs for use in neurological disease.

Agenda—Open public hearing. Interested persons may present data, information, or views, orally or in writing, on issues pending before the committee. Those desiring to make formal presentations should notify the contact person before May 31, 1996, and submit a brief statement of the general nature of the evidence or arguments they wish to present, the names and addresses of proposed participants, and an indication of the approximate time required to make their comments.

Open committee discussion. The committee will discuss product license application 96–0350 for ActivaseTM (alteplase), Genentech, for the management of acute ischemic stroke.